Supplemental New Drug Application submitted to FDA for cabozantinib in combination with nivolumab for treatment of advanced renal cell carcinoma

Submission based is based on results of CheckMate-9ER phase 3 trial comparing the combination with sunitinib in previously untreated patients with advanced or metastatic disease, which met its primary endpoint of significantly improving progression-free survival at final analysis


Biospace Inc.